A review of technological developments in lipid nanoparticle application for mRNA vaccination

Tzu Fu Yeh, Chen Lin, Huang Chih Sung

研究成果: 雜誌貢獻回顧評介論文同行評審

3 引文 斯高帕斯(Scopus)

摘要

Lipid nanoparticle (LNP) technology is critical to the advancement of mRNA vaccines. However, most studies focus on technical aspects and neglect the patent landscape. Moreover, there is a lack of differentiation of LNP technology differences among mRNA, mRNA vaccines, and COVID-19 mRNA vaccines, leading to confusing comparisons. This study fills this gap by analyzing LNP technology in academic journals and patents for mRNA, mRNA vaccines, and COVID-19 mRNA vaccines. The results show (1) academic impact on journal articles and patents, but no direct positive correlation; (2) the USA leads in academic research and patents, with China following closely; and (3) many cited articles have sponsors, indicating the importance of industry-university collaboration. This research aids strategic planning in government, academia, and industry, by providing trend analysis of LNP technology in journals and patents.

原文???core.languages.en_GB???
文章編號2256040
期刊Human Vaccines and Immunotherapeutics
19
發行號2
DOIs
出版狀態已出版 - 2023

指紋

深入研究「A review of technological developments in lipid nanoparticle application for mRNA vaccination」主題。共同形成了獨特的指紋。

引用此